- Home
- ETON vs NYXH Comparison
ETON vs NYXH Comparison
Compare ETON & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- NYXH
- Stock Information
- Founded
- ETON 2017
- NYXH 2009
- Country
- ETON United States
- NYXH Belgium
- Employees
- ETON N/A
- NYXH N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- ETON Health Care
- NYXH Health Care
- Exchange
- ETON Nasdaq
- NYXH Nasdaq
- Market Cap
- ETON 428.5M
- NYXH 222.3M
- IPO Year
- ETON 2018
- NYXH 2021
- Fundamental
- Price
- ETON $17.14
- NYXH $6.26
- Analyst Decision
- ETON Strong Buy
- NYXH Strong Buy
- Analyst Count
- ETON 3
- NYXH 4
- Target Price
- ETON $27.67
- NYXH $14.50
- AVG Volume (30 Days)
- ETON 221.4K
- NYXH 140.5K
- Earning Date
- ETON 05-13-2025
- NYXH 05-16-2025
- Dividend Yield
- ETON N/A
- NYXH N/A
- EPS Growth
- ETON N/A
- NYXH N/A
- EPS
- ETON N/A
- NYXH N/A
- Revenue
- ETON $39,011,000.00
- NYXH $4,680,609.00
- Revenue This Year
- ETON $92.33
- NYXH $342.98
- Revenue Next Year
- ETON $52.62
- NYXH $195.80
- P/E Ratio
- ETON N/A
- NYXH N/A
- Revenue Growth
- ETON 23.29
- NYXH 3.98
- 52 Week Low
- ETON $3.18
- NYXH $5.55
- 52 Week High
- ETON $18.41
- NYXH $12.21
- Technical
- Relative Strength Index (RSI)
- ETON 70.21
- NYXH 40.45
- Support Level
- ETON $16.43
- NYXH $6.03
- Resistance Level
- ETON $17.49
- NYXH $6.66
- Average True Range (ATR)
- ETON 0.85
- NYXH 0.29
- MACD
- ETON 0.18
- NYXH 0.16
- Stochastic Oscillator
- ETON 98.09
- NYXH 48.35
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.